Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Child developmental issues news

Show

From To
BHIVA response to BMJ article on ART in pregnant women living with HIV

We do not support recommendations of "ART in pregnant women living with HIV: a clinical practice guideline" (BMJ, 11/9/17). Other systematic reviews and numerous observational studies show tenofovir to be safe in HIV in pregnancy.

Published
25 September 2017
From
BHIVA
New recommendations aim to help pregnant women with HIV make informed choices

New recommendations on antiretroviral drugs for pregnant women living with HIV can help women make more informed choices about benefits and harms, say a panel of international experts in The BMJ today. The panel recommend older drug combinations instead of the most widely used regimens to help reduce the risk of premature birth and neonatal death - which almost all women said they were extremely keen to avoid.

Published
12 September 2017
From
EurekAlert
Stillbirth more frequent in women with HIV in UK and Ireland than in general population

The stillbirth rate among women living with HIV in the UK and Ireland from 2007 to 2015 was more than twice that of the general

Published
01 August 2017
By
Carole Leach-Lemens
Adolescents with HIV do better in more prosperous African countries, even with treatment

Adolescents who acquired HIV perinatally were less likely to die, grew faster and had better immune restoration on treatment if they lived in upper-middle income

Published
31 July 2017
By
Carole Leach-Lemens
Integrase inhibitors not causing higher rates of adverse birth outcomes, Botswana and French studies show

Dolutegravir-based antiretroviral therapy (ART) started in pregnancy is as safe as efavirenz-based ART, according to a study of birth outcomes at eight maternity wards throughout Botswana accounting for

Published
25 July 2017
By
Carole Leach-Lemens
No evidence that contaminated nelfinavir led to increased risk of birth abnormalities or cancer

HIV-negative infants potentially exposed in utero to doses of the HIV protease inhibitor nelfinavir (Viracept) contaminated with the toxic compound ethyl methyl sulfone (EMS) did not have an

Published
10 October 2016
By
Michael Carter
People shifting from paediatric to adult HIV care have a high risk of ART failure

HIV-positive adolescents and young adults are especially likely to experience the virological failure of their antiretroviral treatment when they move from paediatric to adult HIV care, according to

Published
09 August 2016
By
Michael Carter
HIV—Pregnancy-related issues

Themed issue of CATIE's magazine Treatment Update, with several articles on the safety of antiretrovirals during pregnancy.

Published
20 January 2015
From
CATIE
Poor weight gain during first year of ART associated with increased mortality risk for children with HIV in resource-limited settings

Poor weight gain after starting antiretroviral therapy (ART) is associated with increased mortality risk for children with HIV, investigators report in the online edition of AIDS. An international team

Published
09 December 2014
By
Michael Carter
Risk of birth defects small with HIV drugs

The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine.

Published
30 April 2014
From
EurekAlert
← First12345Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.